You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia
|
|---|---|
| Published in |
Frontiers in immunology, December 2014
|
| DOI | 10.3389/fimmu.2014.00626 |
| Pubmed ID | |
| Authors |
Nicolò Compagno, Giacomo Malipiero, Francesco Cinetto, Carlo Agostini |
| Abstract |
Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of primary hypogammaglobulinemias, significantly reducing the incidence of infectious events. Over the last two decades its use has been extended to secondary antibody deficiencies, particularly those related to hematological disorders as lymphoproliferative diseases (LPDs) and multiple myeloma. In these malignancies, hypogammaglobulinemia can be an intrinsic aspect of the disease or follow chemo-immunotherapy regimens, including anti-CD20 treatment. Other than in LPDs the broadening use of immunotherapy (e.g., rituximab) and immune-suppressive therapy (steroids, sulfasalazine, and mycophenolate mofetil) has extended the occurrence of iatrogenic hypogammaglobulinemia. In particular, in both autoimmune diseases and solid organ transplantation Ig replacement therapy has been shown to reduce the rate of infectious events. Here, we review the existing literature about Ig replacement therapy in secondary hypogammaglobulinemia, with special regard for subcutaneous administration route, a safe, effective, and well-tolerated treatment approach, currently well established in primary immunodeficiencies and secondary hypogammaglobulinemias. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 139 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 139 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 22 | 16% |
| Student > Ph. D. Student | 18 | 13% |
| Researcher | 18 | 13% |
| Student > Postgraduate | 13 | 9% |
| Student > Bachelor | 10 | 7% |
| Other | 28 | 20% |
| Unknown | 30 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 66 | 47% |
| Agricultural and Biological Sciences | 13 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Economics, Econometrics and Finance | 4 | 3% |
| Immunology and Microbiology | 4 | 3% |
| Other | 9 | 6% |
| Unknown | 36 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2022.
All research outputs
#2,391,026
of 25,394,764 outputs
Outputs from Frontiers in immunology
#2,321
of 31,554 outputs
Outputs of similar age
#31,975
of 368,255 outputs
Outputs of similar age from Frontiers in immunology
#14
of 173 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 31,554 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 368,255 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 173 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.